Small-Molecule STING Antagonists for Selective Cytokine Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective small-molecule compounds that can selectively inhibit STING activity, leading to uncontrolled inflammatory responses and associated diseases such as autoinflammatory disorders and inflammation-associated cancers.
Innovation Solution
Development of small-molecule compounds, represented by Formula I, that act as STING antagonists to inhibit STING activity, thereby modulating inflammatory cytokine production and reducing chronic immune-driven diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If STING activity is inhibited to treat autoimmune diseases, then inflammatory cytokine production is reduced, but selective inhibition of STING activity is difficult to achieve
Solution Approach 1:
The patent modifies molecular parameters of STING interaction by developing compounds that target specific structural features of STING. The inhibitors alter binding parameters and interaction dynamics to achieve selective inhibition, distinguishing between STING and related proteins through precise molecular design that exploits parameter differences in the STING protein structure and function.
Solution Approach 2:
The patent introduces small-molecule compounds as intermediary substances that mediate the inhibition of STING activity. These compounds act as molecular intermediaries between the therapeutic agent and STING, providing selective binding and inhibition through their specific molecular structures that interact with STING's active sites or critical regions.
2Measurement precision
If small-molecule STING inhibitors are developed, then selective inhibition is achieved, but compound complexity and development difficulty increase
Solution Approach 1:
The patent segments the complex task of STING inhibition into manageable molecular components. The inhibitors are designed as discrete small-molecule compounds with specific functional groups and structural motifs that can be independently optimized. This segmentation allows systematic development and testing of individual compound classes before combining them into more complex formulations.
Solution Approach 2:
The patent systematically varies molecular parameters such as size, shape, chemical composition, and functional groups to optimize selectivity. By changing these parameters across a series of compounds, the patent identifies optimal structural features that achieve selective STING inhibition while managing complexity through structured parameter exploration rather than random molecular design.
3Productivity
If STING signaling is blocked to treat cancer, then immune response is modulated, but off-target effects and toxicity increase
Solution Approach 1:
The patent applies local quality by designing inhibitors that target specific local regions or domains within STING. Rather than blocking STING globally, the compounds interact with specific structural features or binding sites, allowing localized inhibition that preserves other STING functions. This spatial specificity reduces off-target effects while maintaining therapeutic immune modulation.
Solution Approach 2:
The patent uses small-molecule intermediaries that provide selective binding to STING, acting as molecular filters that prevent off-target interactions. These intermediary compounds are designed to interact specifically with STING's unique structural features, creating a selective barrier that allows therapeutic effect while blocking harmful off-target effects through their specific molecular recognition properties.
Data Source
AI summary
Compounds of the present application or pharmaceutically acceptable salts thereof are capable of interacting with and attenuating the activity of a stimulator of interferon genes (STING) protein. In an embodiment of the invention, antagonist compounds bind to STING protein and attenuate STING downstream signaling. Pharmaceutical compositions and methods involving such compounds as STING modulators are additionally provided herein.